A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

Selidji Todagbe Agnandji; Bertrand Lell; José Francisco Fernandes; Béatrice Peggy Abossolo; Barbara Gaelle Nfono Ondo Methogo; Anita Lumeka Kabwende; Ayola Akim Adegnika; Benjamin Mordmüller; Saadou Issifou; Peter Gottfried Kremsner; Jahit Sacarlal; Pedro Aide; Miguel Lanaspa; John J Aponte; Sonia Machevo; Sozinho Acacio; Helder Bulo; Betuel Sigauque; Eusébio Macete; Pedro Alonso; Salim Abdulla; Nahya Salim; Rose Minja; Maxmillian Mpina; Saumu Ahmed; Ali Mohammed Ali; Ali Takadir Mtoro; Ali Said Hamad; Paul Mutani; Marcel Tanner; Halidou Tinto; Umberto D'Alessandro; Hermann Sorgho; Innocent Valea; Biébo Bihoun; Issa Guiraud; Berenger Kaboré; Olivier Sombié; Robert Tinga Guiguemdé; Jean Bosco Ouédraogo; Mary J Hamel; Simon Kariuki; Martina Oneko; Chris Odero; Kephas Otieno; Norbert Awino; Meredith McMorrow; Vincent Muturi-Kioi; John Lusingu; Thor G Theander; RTS,S Clinical Trials Partnership

doi:10.1056/NEJMoa1208394

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

Selidji Todagbe Agnandji, Bertrand Lell, José Francisco Fernandes, Béatrice Peggy Abossolo, Barbara Gaelle Nfono Ondo Methogo, Anita Lumeka Kabwende, Ayola Akim Adegnika, Benjamin Mordmüller, Saadou Issifou, Peter Gottfried Kremsner, Jahit Sacarlal, Pedro Aide, Miguel Lanaspa, John J Aponte, Sonia Machevo, Sozinho Acacio, Helder Bulo, Betuel Sigauque, Eusébio Macete, Pedro AlonsoSalim Abdulla, Nahya Salim, Rose Minja, Maxmillian Mpina, Saumu Ahmed, Ali Mohammed Ali, Ali Takadir Mtoro, Ali Said Hamad, Paul Mutani, Marcel Tanner, Halidou Tinto, Umberto D'Alessandro, Hermann Sorgho, Innocent Valea, Biébo Bihoun, Issa Guiraud, Berenger Kaboré, Olivier Sombié, Robert Tinga Guiguemdé, Jean Bosco Ouédraogo, Mary J Hamel, Simon Kariuki, Martina Oneko, Chris Odero, Kephas Otieno, Norbert Awino, Meredith McMorrow, Vincent Muturi-Kioi, John Lusingu, Thor G Theander, RTS,S Clinical Trials Partnership

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

638 Citationer (Scopus)

Abstract

The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. We studied infants 6 to 12 weeks of age recruited for the same trial.

Originalsprog	Engelsk
Tidsskrift	New England Journal of Medicine
Vol/bind	367
Udgave nummer	24
Sider (fra-til)	2284-95
Antal sider	12
ISSN	0028-4793
DOI	https://doi.org/10.1056/NEJMoa1208394
Status	Udgivet - 2012

Adgang til dokumentet

10.1056/NEJMoa1208394

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

Agnandji, S. T., Lell, B., Fernandes, J. F., Abossolo, B. P., Methogo, B. G. N. O., Kabwende, A. L., Adegnika, A. A., Mordmüller, B., Issifou, S., Kremsner, P. G., Sacarlal, J., Aide, P., Lanaspa, M., Aponte, J. J., Machevo, S., Acacio, S., Bulo, H., Sigauque, B., Macete, E., ... RTS,S Clinical Trials Partnership (2012). A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. New England Journal of Medicine, 367(24), 2284-95. https://doi.org/10.1056/NEJMoa1208394

Agnandji, ST, Lell, B, Fernandes, JF, Abossolo, BP, Methogo, BGNO, Kabwende, AL, Adegnika, AA, Mordmüller, B, Issifou, S, Kremsner, PG, Sacarlal, J, Aide, P, Lanaspa, M, Aponte, JJ, Machevo, S, Acacio, S, Bulo, H, Sigauque, B, Macete, E, Alonso, P, Abdulla, S, Salim, N, Minja, R, Mpina, M, Ahmed, S, Ali, AM, Mtoro, AT, Hamad, AS, Mutani, P, Tanner, M, Tinto, H, D'Alessandro, U, Sorgho, H, Valea, I, Bihoun, B, Guiraud, I, Kaboré, B, Sombié, O, Guiguemdé, RT, Ouédraogo, JB, Hamel, MJ, Kariuki, S, Oneko, M, Odero, C, Otieno, K, Awino, N, McMorrow, M, Muturi-Kioi, V, Lusingu, J, Theander, TG & RTS,S Clinical Trials Partnership 2012, 'A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants', New England Journal of Medicine, bind 367, nr. 24, s. 2284-95. https://doi.org/10.1056/NEJMoa1208394

@article{ced6252208024056b4748dd23a9a47c9,

title = "A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants",

abstract = "The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. We studied infants 6 to 12 weeks of age recruited for the same trial.",

author = "Agnandji, {Selidji Todagbe} and Bertrand Lell and Fernandes, {Jos{\'e} Francisco} and Abossolo, {B{\'e}atrice Peggy} and Methogo, {Barbara Gaelle Nfono Ondo} and Kabwende, {Anita Lumeka} and Adegnika, {Ayola Akim} and Benjamin Mordm{\"u}ller and Saadou Issifou and Kremsner, {Peter Gottfried} and Jahit Sacarlal and Pedro Aide and Miguel Lanaspa and Aponte, {John J} and Sonia Machevo and Sozinho Acacio and Helder Bulo and Betuel Sigauque and Eus{\'e}bio Macete and Pedro Alonso and Salim Abdulla and Nahya Salim and Rose Minja and Maxmillian Mpina and Saumu Ahmed and Ali, {Ali Mohammed} and Mtoro, {Ali Takadir} and Hamad, {Ali Said} and Paul Mutani and Marcel Tanner and Halidou Tinto and Umberto D'Alessandro and Hermann Sorgho and Innocent Valea and Bi{\'e}bo Bihoun and Issa Guiraud and Berenger Kabor{\'e} and Olivier Sombi{\'e} and Guiguemd{\'e}, {Robert Tinga} and Ou{\'e}draogo, {Jean Bosco} and Hamel, {Mary J} and Simon Kariuki and Martina Oneko and Chris Odero and Kephas Otieno and Norbert Awino and Meredith McMorrow and Vincent Muturi-Kioi and John Lusingu and Theander, {Thor G} and {RTS,S Clinical Trials Partnership}",

year = "2012",

doi = "10.1056/NEJMoa1208394",

language = "English",

volume = "367",

pages = "2284--95",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "24",

}

TY - JOUR

T1 - A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

AU - Agnandji, Selidji Todagbe

AU - Lell, Bertrand

AU - Fernandes, José Francisco

AU - Abossolo, Béatrice Peggy

AU - Methogo, Barbara Gaelle Nfono Ondo

AU - Kabwende, Anita Lumeka

AU - Adegnika, Ayola Akim

AU - Mordmüller, Benjamin

AU - Issifou, Saadou

AU - Kremsner, Peter Gottfried

AU - Sacarlal, Jahit

AU - Aide, Pedro

AU - Lanaspa, Miguel

AU - Aponte, John J

AU - Machevo, Sonia

AU - Acacio, Sozinho

AU - Bulo, Helder

AU - Sigauque, Betuel

AU - Macete, Eusébio

AU - Alonso, Pedro

AU - Abdulla, Salim

AU - Salim, Nahya

AU - Minja, Rose

AU - Mpina, Maxmillian

AU - Ahmed, Saumu

AU - Ali, Ali Mohammed

AU - Mtoro, Ali Takadir

AU - Hamad, Ali Said

AU - Mutani, Paul

AU - Tanner, Marcel

AU - Tinto, Halidou

AU - D'Alessandro, Umberto

AU - Sorgho, Hermann

AU - Valea, Innocent

AU - Bihoun, Biébo

AU - Guiraud, Issa

AU - Kaboré, Berenger

AU - Sombié, Olivier

AU - Guiguemdé, Robert Tinga

AU - Ouédraogo, Jean Bosco

AU - Hamel, Mary J

AU - Kariuki, Simon

AU - Oneko, Martina

AU - Odero, Chris

AU - Otieno, Kephas

AU - Awino, Norbert

AU - McMorrow, Meredith

AU - Muturi-Kioi, Vincent

AU - Lusingu, John

AU - Theander, Thor G

AU - RTS,S Clinical Trials Partnership

PY - 2012

Y1 - 2012

N2 - The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. We studied infants 6 to 12 weeks of age recruited for the same trial.

AB - The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. We studied infants 6 to 12 weeks of age recruited for the same trial.

U2 - 10.1056/NEJMoa1208394

DO - 10.1056/NEJMoa1208394

M3 - Journal article

C2 - 23136909

SN - 0028-4793

VL - 367

SP - 2284

EP - 2295

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 24

ER -